Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Oct 19;28(5):4234-4246.
doi: 10.3390/curroncol28050359.

Omental Macrophagic "Crown-like Structures" Are Associated with Poor Prognosis in Advanced-Stage Serous Ovarian Cancer

Affiliations

Omental Macrophagic "Crown-like Structures" Are Associated with Poor Prognosis in Advanced-Stage Serous Ovarian Cancer

Yu-Ling Liang et al. Curr Oncol. .

Abstract

The tumor microenvironment is a well-recognized framework in which immune cells present in the tumor microenvironment promote or inhibit cancer formation and development. A crown-like structure (CLS) has been reported as a dying or dead adipocyte surrounded by a 'crown' of macrophages within adipose tissue, which is a histologic hallmark of the inflammatory process in this tissue. CLSs have also been found to be related to formation, progression and prognosis of some types of cancer. However, the presence of CLSs in the omentum of advanced-stage high-grade serous ovarian carcinoma (HGSOC) has not been thoroughly investigated. By using CD68, a pan-macrophage marker, and CD163, an M2-like polarization macrophage marker, immunohistochemistry (IHC) was performed to identify tumor-associated macrophages (TAMs) and CLSs. This retrospective study analyzed 116 patients with advanced-stage HGSOC who received complete treatment and had available clinical data from July 2008 through December 2016 at National Cheng Kung University Hospital (NCKUH) (Tainan, Taiwan). Based on multivariate Cox regression analysis, patients with omental CD68+ CLSs had poor OS (median survival: 24 vs. 38 months, p = 0.001, hazard ratio (HR): 2.26, 95% confidence interval (CI): 1.41-3.61); patients with omental CD163+ CLSs also had poor OS (median survival: 22 vs. 36 months, HR: 2.14, 95%CI: 1.33-3.44, p = 0.002). Additionally, patients with omental CD68+ or CD163+ CLSs showed poor PFS (median survival: 11 vs. 15 months, HR: 2.28, 95%CI: 1.43-3.64, p = 0.001; median survival: 11 vs. 15 months, HR: 2.17, 95%CI: 1.35-3.47, respectively, p = 0.001). Conversely, the density of CD68+ or CD163+ TAMs in ovarian tumors was not associated with patient prognosis in advanced-stage HGSOC in our cohort. In conclusion, we, for the first time, demonstrate that the presence of omental CLSs is associated with poor prognosis in advanced-stage HGSOC.

Keywords: advanced-stage high-grade serous ovarian carcinoma (HGSOC); crown-like structure (CLS); omentum; tumor microenvironment.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Representative image of CLS and TAMs by immunohistochemical staining for CD68 and ImageJ software-assisted images. (A,D,G), H&E staining; (B,E,H), IHC CD68 staining; (C,F,I), ImageJ images. In (C), note that there are two adipocytes completely surrounded by CD68-positive macrophages (arrows), counted as two CD68+ CLSs. (G) For TAM density, the area with the greatest concentration of CD68-stained TAMs was identified. Then, five fields (red box, four quadrants and a central area, each field contained 0.04 mm2) under 100× magnification were selected, and the number of CD68+ macrophages was counted under 200× magnification with the assistance of ImageJ software (I).
Figure 2
Figure 2
Patients with advanced-stage HGSOC with omental CD68+ or CD163+ CLSs have poorer OS and PFS than those without omental CLSs. In advanced-stage HGSOC (n = 116), patients with omental CD68+ CLSs (no. ≥ 1) (A) or omental CD163+ CLSs (no. ≥ 1) (B) had worse OS (median survival: 24 vs. 38 months; 22 vs. 36 months, respectively, p = 0.001; p = 0.002). Patients with omental CD68+ (C) or CD163+ (D) CLSs had poor PFS (median survival: 11 vs. 15 months; 11 vs. 15 months, respectively p = 0.001, 0.001).
Figure 3
Figure 3
Patients with advanced-stage HGSOC with a low density of omental CD68+ or CD163+ om-TAMs had a poor prognosis in terms of OS. (A,B) Patients with a low density of omental CD68+ or CD163+ om-TAMs had poor OS (median survival: 27 vs. 47 months; 26 vs. 46 months, p = 0.023; p = 0.098). (C,D) The density of omental CD68+ or CD163+ om-TAMs was not associated with PFS (median survival: 13 vs. 20 months; 13 vs. 18 months, p = 0.225, p = 0.547). (E,F) The ratio of omental CD68+/ CD163+ om-TAM was not associated with OS or PFS (p = 0.50; p = 0.299).

References

    1. Mantovani A., Marchesi F., Malesci A., Laghi L., Allavena P. Tumour-associated macrophages as treatment targets in oncology. Nat. Rev. Clin. Oncol. 2017;14:399–416. doi: 10.1038/nrclinonc.2016.217. - DOI - PMC - PubMed
    1. Cassetta L., Pollard J.W. Targeting macrophages: Therapeutic approaches in cancer. Nat. Rev. Drug Discov. 2018;17:887–904. doi: 10.1038/nrd.2018.169. - DOI - PubMed
    1. Zhang Q.W., Liu L., Gong C.Y., Shi H.S., Zeng Y.H., Wang X.Z., Zhao Y.W., Wei Y.Q. Prognostic significance of tumor-associated macrophages in solid tumor: A meta-analysis of the literature. PLoS ONE. 2012;7:e50946. doi: 10.1371/journal.pone.0050946. - DOI - PMC - PubMed
    1. Ruffell B., Coussens L.M. Macrophages and therapeutic resistance in cancer. Cancer Cell. 2015;27:462–472. doi: 10.1016/j.ccell.2015.02.015. - DOI - PMC - PubMed
    1. Kübler K., Ayub T.H., Weber S.K., Zivanovic O., Abramian A., Keyver-Paik M.D., Mallmann M.R., Kaiser C., Serçe N.B., Kuhn W., et al. Prognostic significance of tumor-associated macrophages in endometrial adenocarcinoma. Gynecol. Oncol. 2014;135:176–183. doi: 10.1016/j.ygyno.2014.08.028. - DOI - PubMed

Publication types